A study recently published in NEJM Evidence introduces a new predictive score to help clinicians identify patients at risk of developing liver cancer among those with advanced chronic liver disease. The study used data from over 3000 patients and analyzed several factors known to affect liver cancer risk. The new algorithm, referred to as PLEASE score, stratifies patients into high-risk and low-risk groups for hepatocellular carcinoma based on five core factors: liver stiffness measurement by a range of elastography techniques, platelet count, age, sex, and liver disease etiology. Patients scoring four or more points were regarded at high risk and might benefit from more frequent screening, while low-risk patients, with scores under four, may need less frequent monitoring. With this approach, researchers aim to tailor screening intervals, making liver cancer surveillance more targeted and potentially improving outcomes for patients at the highest risk to develop liver cancer.
Jonel Trebicka, Senior Research Affiliate at EF CLIF, Spain and Principal Investigator at University of Münster, Germany, explains: “Currently, the general recommendation is to conduct liver cancer screenings every six months for all patients with cirrhosis, without adjusting for individual variations in risk levels within this group. According to recent data, only 10% of patients with advanced chronic liver disease actually receive this screening, often due to follow-up difficulties or limited healthcare resources. This new algorithm will direct screening efforts toward high-risk patients, making closer monitoring easier and more acceptable for them. For patients at very low risk, longer intervals between screenings will help save resources without compromising care.”
Wenyi Gu, postdoctoral researcher at University Hospital Münster, Germany, and first author in the paper, says: “Liver stiffness measurements (LSM) play a pivotal role in identifying patients at elevated risk for liver cancer. Increased liver stiffness often indicates more advanced fibrosis and inflammation, which are conditions closely linked to a higher likelihood of hepatocellular carcinoma development. Alongside LSM, factors such as age, sex, platelet count, liver disease etiology, and coexisting conditions like viral hepatitis or steatosis allow us to gain a comprehensive understanding of a patient’s cancer risk. These factors combined are essential for accurate, personalized risk assessment in patients with advanced chronic liver diseases, enabling us to pinpoint those who may benefit most from intensive surveillance.”
This new approach will help clinicians prioritize follow-up for patients at highest risk, while limiting screening frequency for those at lower risk.“This tool has the potential to significantly refine current liver cancer screening practices by offering a risk-stratified approach. Patients identified in the high-risk category can be monitored more closely with biannual screening, while lower-risk individuals may require less frequent follow-up. By focusing resources on patients most in need, we aim to improve early detection of hepatocellular carcinoma and optimize screening protocols, ultimately enhancing patient outcomes in advanced chronic liver disease management”, Gu explains.
“We are currently testing this tool in a multicenter randomized controlled trial across Germany, with partial funding from the German Federal Ministry of Education and Research. We’re hopeful for positive results from the DETECT study, which is now open and recruiting participants at seven German university hospitals”, Trebicka adds.
Other authors in the study are Victor de Lédinghen, Christophe Aubé, Aleksander Krag, Christian Strassburg, Laurent Castéra, Jérôme Dumortier, Mireen Friedrich-Rust, Stanislas Pol, Ivica Grgurevic, Yasmin Zeleke, Michael Praktiknjo, Robert Schierwagen, Sabine Klein, Sven Francque, Halima Gottfriedová, Ioan Sporea, Philipp Schindler, Florian Rennebaum, Maximilian Joseph Brol, Martin Schulz, Frank Erhard Uschner, Julia Fischer, Cristina Margini, Wenping Wang, Adèle Delamarre, Jan Best, Ali Canbay, David Josef Maria Bauer, Benedikt Simbrunner, Georg Semmler, Thomas Reiberger, Jérôme Boursier, Ditlev Nytoft Rasmussen, Valérie Vilgrain, Aymeric Guibal, Stefan Zeuzem, Camille Vassord, Luisa Vonghia, Renata Šenkeříková, Alina Popescu, Annalisa Berzigotti, Wim Laleman, Maja Thiele, and Christian Jansen.
Gu W, de Lédinghen V, Aubé C, Krag A, Strassburg C, Castéra L, Dumortier J, Friedrich-Rust M, Pol S, Grgurevic I, Zeleke Y, Praktiknjo M, Schierwagen R, Klein S, Francque S, Gottfriedová H, Sporea I, Schindler P, Rennebaum F, Brol MJ, Schulz M, Uschner FE, Fischer J, Margini C, Wang W, Delamarre A, Best J, Canbay A, Bauer DJM, Simbrunner B, Semmler G, Reiberger T, Boursier J, Rasmussen DN, Vilgrain V, Guibal A, Zeuzem S, Vassord C, Vonghia L, Šenkeříková R, Popescu A, Berzigotti A, Laleman W, Thiele M, Jansen C, Trebicka J. NEJM Evid. 3(11): EVIDoa2400062. DOI: 10.1056/EVIDoa2400062. Epub 22 October 2024.
European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
© European Foundation for the Study of Chronic Liver Failure 2024
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |